» Articles » PMID: 18353445

Mechanism-based Pharmacokinetic-pharmacodynamic (PK-PD) Modeling in Translational Drug Research

Overview
Specialty Pharmacology
Date 2008 Mar 21
PMID 18353445
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

The use of pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research is a promising approach that provides better understanding of drug efficacy and safety. It is applied to predict efficacy and safety in humans using in vitro bioassay and/or in vivo animal data. Current research in PK-PD modeling focuses on the development of mechanism-based models with improved extrapolation and prediction properties. A key element in mechanism-based PK-PD modeling is the explicit distinction between parameters for describing (i) drug-specific properties and (ii) biological system-specific properties. Mechanism-based PK-PD models contain specific expressions for the characterization of processes on the causal path between drug exposure and drug response. The different terms represent: target-site distribution, target binding and activation and transduction. Ultimately, mechanism-based PK-PD models will also characterize the interaction of the drug effect with disease processes and disease progression. In this review, the principles of mechanism-based PK-PD modeling are described and illustrated by recent applications.

Citing Articles

Improving neuroendocrine tumor treatments with mathematical modeling: lessons from other endocrine cancers.

Metzcar J, Guenter R, Wang Y, Baker K, Lines K Endocr Oncol. 2025; 5(1):e240025.

PMID: 39949335 PMC: 11825163. DOI: 10.1530/EO-24-0025.


Impact of Dapagliflozin on Hepatic Lipid Metabolism and a Dynamic Model of Ketone Body Levels.

Wan Z, Yuan M, Liu Z, Cai Y, He H, Hao K AAPS J. 2025; 27(1):38.

PMID: 39900889 DOI: 10.1208/s12248-025-01024-x.


A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity.

Niazi S Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004421 PMC: 10675618. DOI: 10.3390/ph16111556.


Modeling the protein binding non-linearity in population pharmacokinetic model of valproic acid in children with epilepsy: a systematic evaluation study.

Zhang L, Liu M, Qin W, Shi D, Mao J, Li Z Front Pharmacol. 2023; 14:1228641.

PMID: 37869748 PMC: 10587682. DOI: 10.3389/fphar.2023.1228641.


Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer.

Zhu J, Zhang Y, Zhao Y, Zhang J, Hao K, He H Pharmaceutics. 2023; 15(9).

PMID: 37765243 PMC: 10535808. DOI: 10.3390/pharmaceutics15092274.